Compare GTN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTN | BIOA |
|---|---|---|
| Founded | 1897 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.5M | 481.0M |
| IPO Year | 1996 | 2024 |
| Metric | GTN | BIOA |
|---|---|---|
| Price | $4.67 | $8.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $8.50 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 804.3K | 546.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | N/A | ★ 66.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,095,000,000.00 | $8,995,000.00 |
| Revenue This Year | $13.89 | $720.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $4.94 |
| 52 Week High | $6.44 | $25.96 |
| Indicator | GTN | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 31.40 |
| Support Level | $4.21 | N/A |
| Resistance Level | $4.70 | $10.25 |
| Average True Range (ATR) | 0.19 | 0.45 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 28.26 | 23.46 |
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios. The company's segments include Broadcasting and Production Companies. The majority of revenue is derived from broadcast and digital advertising and from retransmission consent fees.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.